These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 34477539)

  • 1.
    Thamaraikani T; Karnam M; Velapandian C
    CNS Neurol Disord Drug Targets; 2022; 21(4):343-353. PubMed ID: 34477539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benomyl, aldehyde dehydrogenase, DOPAL, and the catecholaldehyde hypothesis for the pathogenesis of Parkinson's disease.
    Casida JE; Ford B; Jinsmaa Y; Sullivan P; Cooney A; Goldstein DS
    Chem Res Toxicol; 2014 Aug; 27(8):1359-61. PubMed ID: 25045800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease.
    Fitzmaurice AG; Rhodes SL; Lulla A; Murphy NP; Lam HA; O'Donnell KC; Barnhill L; Casida JE; Cockburn M; Sagasti A; Stahl MC; Maidment NT; Ritz B; Bronstein JM
    Proc Natl Acad Sci U S A; 2013 Jan; 110(2):636-41. PubMed ID: 23267077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease.
    Goldstein DS; Sullivan P; Cooney A; Jinsmaa Y; Kopin IJ; Sharabi Y
    J Neurochem; 2015 Apr; 133(1):14-25. PubMed ID: 25645689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldehyde dehydrogenase 2 in sporadic Parkinson's disease.
    Michel TM; Käsbauer L; Gsell W; Jecel J; Sheldrick AJ; Cortese M; Nickl-Jockschat T; Grünblatt E; Riederer P
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S68-72. PubMed ID: 24262192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective effects of aldehyde dehydrogenase 2 activation in rotenone-induced cellular and animal models of parkinsonism.
    Chiu CC; Yeh TH; Lai SC; Wu-Chou YH; Chen CH; Mochly-Rosen D; Huang YC; Chen YJ; Chen CL; Chang YM; Wang HL; Lu CS
    Exp Neurol; 2015 Jan; 263():244-53. PubMed ID: 25263579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teleost Model as an Alternative in Parkinson's Disease.
    Manasa K; Chitra V; Tamilanban T
    Neurol India; 2020; 68(5):979-984. PubMed ID: 33109837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.
    Goldstein DS; Sullivan P; Holmes C; Miller GW; Alter S; Strong R; Mash DC; Kopin IJ; Sharabi Y
    J Neurochem; 2013 Sep; 126(5):591-603. PubMed ID: 23786406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complex I deficiency and dopaminergic neuronal cell loss in parkin-deficient zebrafish (Danio rerio).
    Flinn L; Mortiboys H; Volkmann K; Köster RW; Ingham PW; Bandmann O
    Brain; 2009 Jun; 132(Pt 6):1613-23. PubMed ID: 19439422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldehyde dehydrogenase (ALDH) in Alzheimer's and Parkinson's disease.
    Grünblatt E; Riederer P
    J Neural Transm (Vienna); 2016 Feb; 123(2):83-90. PubMed ID: 25298080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons.
    Dragicevic E; Poetschke C; Duda J; Schlaudraff F; Lammel S; Schiemann J; Fauler M; Hetzel A; Watanabe M; Lujan R; Malenka RC; Striessnig J; Liss B
    Brain; 2014 Aug; 137(Pt 8):2287-302. PubMed ID: 24934288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parkinson's disease--redox mechanisms.
    Adams JD; Chang ML; Klaidman L
    Curr Med Chem; 2001 Jun; 8(7):809-14. PubMed ID: 11375751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential Alterations in Metabolism and Proteolysis-Related Proteins in Human Parkinson's Disease Substantia Nigra.
    Grünblatt E; Ruder J; Monoranu CM; Riederer P; Youdim MB; Mandel SA
    Neurotox Res; 2018 Apr; 33(3):560-568. PubMed ID: 29218503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation.
    Liu G; Yu J; Ding J; Xie C; Sun L; Rudenko I; Zheng W; Sastry N; Luo J; Rudow G; Troncoso JC; Cai H
    J Clin Invest; 2014 Jul; 124(7):3032-46. PubMed ID: 24865427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease.
    Wey MC; Fernandez E; Martinez PA; Sullivan P; Goldstein DS; Strong R
    PLoS One; 2012; 7(2):e31522. PubMed ID: 22384032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldehyde dehydrogenase variation enhances effect of pesticides associated with Parkinson disease.
    Fitzmaurice AG; Rhodes SL; Cockburn M; Ritz B; Bronstein JM
    Neurology; 2014 Feb; 82(5):419-26. PubMed ID: 24491970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70.
    Mandel S; Grunblatt E; Riederer P; Amariglio N; Jacob-Hirsch J; Rechavi G; Youdim MB
    Ann N Y Acad Sci; 2005 Aug; 1053():356-75. PubMed ID: 16179542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy.
    Goldstein DS; Sullivan P; Holmes C; Kopin IJ; Sharabi Y; Mash DC
    Parkinsonism Relat Disord; 2015 Jun; 21(6):567-72. PubMed ID: 25829070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidation of dopamine to aminochrome as a mechanism for neurodegeneration of dopaminergic systems in Parkinson's disease. Possible neuroprotective role of DT-diaphorase.
    Graumann R; Paris I; Martinez-Alvarado P; Rumanque P; Perez-Pastene C; Cardenas SP; Marin P; Diaz-Grez F; Caviedes R; Caviedes P; Segura-Aguilar J
    Pol J Pharmacol; 2002; 54(6):573-9. PubMed ID: 12866711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective effect of IDPU (1-(7-imino-3-propyl-2,3-dihydrothiazolo [4,5-d]pyrimidin-6(7H)-yl)urea) in 6-OHDA induced rodent model of hemiparkinson's disease.
    Kumari N; Agrawal S; Kumari R; Sharma D; Luthra PM
    Neurosci Lett; 2018 May; 675():74-82. PubMed ID: 29567422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.